08:38 AM EDT, 06/17/2025 (MT Newswires) -- Lyell Immunopharma ( LYEL ) said Tuesday its phase 1/2 trial of LYL314 achieved "robust" clinical responses in patients with large B-cell lymphoma treated in the third- or later-line setting.

The trial showed an 88% overall response rate and a 72% complete response rate among 25 evaluable patients, according to Lyell.

The company also said 71% of patients who achieved complete response remained in complete response for at least six months.

Lyell said it has initiated a pivotal single-arm trial in patients with relapsed or refractory large B-cell lymphoma treated in the third- or later-line setting, and plans to launch a pivotal trial in 2026 to evaluate LYL314 in the second-line setting.

Shares of Lyell Immunopharma ( LYEL ) were up nearly 7% in recent premarket activity.